| Client Successes |
Orphan Drug Act
Our lawyers represented clients under the Orphan Drug Act, which is credited with giving rise to the biotechnology industry, through its provision of seven years of marketing exclusivity to companies that develop drugs or biologics for patients with rare diseases.
|
Reimbursement Strategies in the Fight Against Cancer
We represented a leading biotechnology company in increasing hospital outpatient reimbursement for supportive anti-cancer therapy.
|
Successful DRG Reclassification
Our lawyers provided counsel to a leading biotechnology company and cancer center in obtaining a DRG reclassification for hospital inpatient reimbursement for therapy for renal cell carcinoma and melanoma.
|
First
Previous
1
Next
Last